Page 54 - 202002
P. 54
[16] DRUCKER DJ. Mechanisms of [22] KAKU K, YAMADA Y, WATADA
Action and Therapeutic Application of H, et al. Safety and efficacy of once-
Glucagon-like Peptide-1 [J]. Cell Metab, weekly semaglutide vs additional oral
2018,27(4):740-756. antidiabetic drugs in Japanese people
with inadequately controlled type 2
[17] JENSEN L, HELLEBERG H,
ROFFEL A, et al. Absorption, metabolism diabetes: A randomized trial [J]. Diabetes
and excretion of the GLP-1 analogue Obes Metab, 2018,20(5):1202-1212.
semaglutide in humans and nonclinical [23] SORLI C, HARASHIMA SI,
species [J]. Eur J Pharm Sci, 2017, TSOUKAS GM, et al. Efficacy and safety
104:31-41. of once-weekly semaglutide monotherapy
versus placebo in patients with type 2
[18] MARBURY TC, FLINT A,
JACOBSEN JB, et al. Pharmacokinetics diabetes (SUSTAIN 1): a double-blind,
and Tolerability of a Single Dose of randomised, placebo-controlled, parallel-
Semaglutide, a Human Glucagon-Like group, multinational, multicentre phase 3a
Peptide-1 Analog, in Subjects With and trial [J]. Lancet Diabetes Endocrinol,
Without Renal Impairment [J]. Clin 2017,5(4):251-260.
Pharmacokinet, 2017,56(11):1381-1390. [24] RODBARD HW, LINGVAY I,
REED J, et al. Semaglutide Added to
[19] JENSEN L, KUPCOVA V,
AROLD G, et al. Pharmacokinetics and Basal Insulin in Type 2 Diabetes
tolerability of semaglutide in people with (SUSTAIN 5): A Randomized, Controlled
hepatic impairment [J]. Diabetes Obes Trial [J]. J Clin Endocrinol Metab,
Metab, 2018,20(4):998-1005. 2018,103(6):2291-2301.
[25] AHRÉN B, MASMIQUEL L,
[20] IKUSHIMA I, JENSEN L, FLINT
A, ,et al. A Randomized Trial Investigating KUMAR H, et al. Efficacy and safety of
the Pharmacokinetics, once-weekly semaglutide versus once-
Pharmacodynamics, and Safety of daily sitagliptin as an add-on to
Subcutaneous Semaglutide Once-Weekly metformin, thiazolidinediones, or both, in
in Healthy Male Japanese and Caucasian patients with type 2 diabetes (SUSTAIN
Subjects [J]. Adv Ther, 2018,35(4):531- 2): a 56-week, double-blind, phase 3a,
544. randomised trial [J]. Lancet Diabetes
Endocrinol, 2017,5(5):341-354.
[21] SEINO Y, TERAUCHI Y,
OSONOI T, et al. Safety and efficacy of [26] ARODA VR, BAIN SC, CARIOU
semaglutide once weekly vs sitagliptin B, et al. Efficacy and safety of once-
once daily, both as monotherapy in weekly semaglutide versus once-daily
Japanese people with type 2 diabetes [J]. insulin glargine as add-on to metformin
Diabetes Obes Metab, 2018,20(2):378- (with or without sulfonylureas) in insulin-
388. naive patients with type 2 diabetes
(SUSTAIN 4): a randomised, open-label,
c͂̽ḤḤc
